FDA Approves Zejula as Maintenance Therapy for Ovarian, Other Women’s Cancers

FDA Approves Zejula as Maintenance Therapy for Ovarian, Other Women’s Cancers
The United States has approved Tesaro’s Zejula (niraparib) as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The Federal Drug Administration sign-off indicates that regulators believe Zejula’s can delay cancer growth in patients who have shown a complete or partial response to platinum-based chemotherapy. “Maintenance therapy is an important part

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , , .

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

Leave a Comment

Your email address will not be published. Required fields are marked *